Navigation Links
Vista Partners Initiates Coverage on Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE)
Date:5/20/2008

atives. Cethrin, a recombinant-protein-based drug designed to promote nerve repair after acute spinal cord injury, demonstrated positive interim results in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, Oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company has a robust molecular imaging development program targeting diagnosis of Parkinson's disease and potentially dementia. The Company's lead molecular imaging product candidate is Altropane which is in Phase III clinical trials for the diagnosis of Parkinsonian Syndromes including Parkinson's Disease. The Company has research collaborations with Harvard Medical School and Children's Hospital Boston.

Contact:

Vista Partners LLC

Ross Silver

(415) 738-6229

info@vistap.com

http://www.vistap.com


'/>"/>
SOURCE Vista Partners
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
2. Vista Partners Initiates Coverage on Raptor Pharmaceuticals Corp.
3. Synvista Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. Vista Partners Updates Coverage on Raptor Pharmaceuticals Corp.
5. Boston Scientific Agrees To Sell Fluid Management and Venous Access Businesses to Avista Capital Partners for $425 Million
6. Avista Capital Partners Completes Acquisition of Bristol-Myers Squibb Medical Imaging
7. Accipiter Capital Management Opposes Acquisition of VistaCare, Inc. by Odyssey Healthcare, Inc.
8. Accipiter Capital Management Reaffirms Its Opposition to the Acquisition of VistaCare, Inc. by Odyssey Healthcare, Inc.
9. Boston Scientific Completes Sale of Fluid Management and Venous Access Businesses to Avista Capital Partners
10. Synvista Therapeutics to Present at the Roth 20th Annual OC Growth Stock Conference
11. Avista Capital Partners Enhances Energy Practice With Appointment of Gerhard Kurz
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2008)...rst Walkathon to Benefit Muscular Dystrophy Resear...ugust 29, 2008 -- Students, faculty and staff from...I), in New Jersey, raised $11,000 for muscular dys...ek. Proceeds from the event are in support of loc... The all-volunteer event was attended by more than...
(Date:8/29/2008)...9 /PRNewswire/ --, - MYA Cosmetic Surgery Seems t... Stars but the big Question is who Will be Next?, ...d being on national,television for an hour each ni...the way you look. For many previous Big Brother co...the house contestants may undoubtedly spend,hours ...
(Date:8/29/2008)...D presents Telemedicine Encounter Management Syste...ations as a possible solution to national health c...ord, MA (PRWEB) August 29, 2008 -- If there has be...ers at the Democratic National Convention it has b...ational health care issues., , ,Our Democratic lea...
(Date:8/29/2008)...usted life science software provider allows federa...ia GSA. , Reston, VA (PRW... software engineering firm dedicated to the life s...vices Administration (GSA) Contract. The GSA IT Sc...bility to conveniently engage 5AM Solutions, softw...
Breaking Medicine News(10 mins):Health News:Sanford-Brown Institute - Iselin Raises $11,000 for Ryan's Quest 2Health News:MYA Makes Big Brother Stars Amazing! 2Health News:MYA Makes Big Brother Stars Amazing! 3Health News:AMD Global Telemedicine Inc. Invited to Attend Democratic National Convention 2Health News:Federal and State Agencies Have Easier Access to 5AM Solutions' Award-Winning Software Services 2
... researchers say girls are affected more than boys...this difference between girls and boys being diagn...process of conducting a study which aims to establ... and why. The study included 307 healthy children ...
...risk factors may reduce the risk of dementia, say ... which shows that cardiovascular risk factors in m...ementia in old age. Risk factors for cardiovascul...ertension, diabetes and smoking. Each of these car...
...the only thing diabetics need to do to avoid the p...ay researchers based on findings of a recent study...ing, and high blood pressure, is found to exacerba...hers proper blood sugar control can markedly decre...
... researchers say weight gain after age 18 can be a...ostmenopausal women who // are not taking hormone ... nearly 62,000 women, ages 50 to 74, by asking the... current weight. Since then, the women have been p...
Other Medicine News:
(Date:8/26/2008)...- XTENT, Inc.,(Nasdaq: XTN...low-up data,from the CUSTOM II trial was published...rnal, EuroIntervention. The lead author of the art... Medical Center Utrecht, Utrecht,The Netherlands ...linical,sites across Europe., The one-year CUSTOM...
(Date:8/25/2008)...and Treatment Strategies--, PHILADELPHIA, Aug. 25...ered gene mutations that are the main cause of the...astoma. In addition, the researchers found,that th...isk forms of,non-inherited neuroblastoma, the more...bles us to offer the first genetic tests to famili...
(Date:8/25/2008)...reatment and Japanese Development Studies ...rk, August 25 /- Genmab has...ab in chronic lymphocytic,leukemia and non-Hodgkin...ay plans to begin four studies of,ofatumumab in ch...n-Hodgkin,s lymphoma (NHL) this year., "Genmab an...
(Date:8/21/2008)...paign Addresses Knowledge Gap, Educates, American...ant Choice to Make thi...- A new survey of parents of,eight-to-17-year olds...hings they believe they can do to help protect aga...uidelines state that getting an annual flu,vaccina...
Breaking Medicine Technology:XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 2XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 3XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 4Gene That Causes Childhood Cancer Neuroblastoma Is Found 2Gene That Causes Childhood Cancer Neuroblastoma Is Found 3Gene That Causes Childhood Cancer Neuroblastoma Is Found 4Genmab Announces Upcoming Ofatumumab Studies 2Genmab Announces Upcoming Ofatumumab Studies 3Genmab Announces Upcoming Ofatumumab Studies 4Survey Shows Parents' Best Intentions Out of Step with Expert Recommendations in Protecting Kids from Flu 2Survey Shows Parents' Best Intentions Out of Step with Expert Recommendations in Protecting Kids from Flu 3Survey Shows Parents' Best Intentions Out of Step with Expert Recommendations in Protecting Kids from Flu 4Survey Shows Parents' Best Intentions Out of Step with Expert Recommendations in Protecting Kids from Flu 5Computer predicts anti cancer molecules 6024 1First semiconductor based PET scanner demonstrates potential to aid in early diagnosis of disease 6022 1First semiconductor based PET scanner demonstrates potential to aid in early diagnosis of disease 6022 2Michigan Tech scientist models molecular switch 6020 1Michigan Tech scientist models molecular switch 6020 2TalkAIDS 3A A 26PI Wellness Center Launches a New Anti Stigma Campaign With International Star Joan Chen 22007 1TalkAIDS 3A A 26PI Wellness Center Launches a New Anti Stigma Campaign With International Star Joan Chen 22007 2
...Spain--(BUSINESS WIRE)--Apr 11, 2007 - New data,su...X-950), one of,the most advanced investigational o...itis C virus (HCV) infection, will be presented,at...on for the,Study of the Liver (EASL) in Barcelona ...aprevir have been accepted for presentation,at the...
...SCO, April 11, 2007 /PRNewswire-FirstCall/ -- Vica...luenza vaccine,formulated with the company,s Vaxfe...ntibody responses than an unformulated vaccine,at ...e. Formulation,of sanofi pasteur,s Fluzone(R) comm...early 10-fold reduction in vaccine,dose while gene...
Other Medicine Technology:Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 2Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 3Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 4Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 5Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 6Vical's Vaxfectin Adjuvant Achieves Dose-Sparing Effect With,Seasonal Influenza Vaccine 2Vical's Vaxfectin Adjuvant Achieves Dose-Sparing Effect With,Seasonal Influenza Vaccine 3Vical's Vaxfectin Adjuvant Achieves Dose-Sparing Effect With,Seasonal Influenza Vaccine 4Vical's Vaxfectin Adjuvant Achieves Dose-Sparing Effect With,Seasonal Influenza Vaccine 5
The generously sized STERILE VIEW Monk Hood from DePuy provides splash protection in the chin and neck areas from body fluids and liquids. Shoulder cut outs and ties ensure a comfortable fit. This pr
STERILE VIEW Barrier Sleeves combine superior protection against contaminants with unsurpassed comfort and the convenience of universal sizing.
...K System rede phines sharpness and efficiency wit... for penetrating keratoplasty. Advanced trephine ...ing edge to achieve the critical fit needed for su... and fully customized system enables surgeons to s...
Digital Imaging for Optical Screening:,Diabetes, Glaucoma Macular Degeneration, and other retinal disease.
Medicine Products: